Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery

Glucagon-like peptide-1 receptor agonists and combination incretin medications (hereafter referred to as GLP-1 RAs) represent a paradigm shift in the management of obesity, approaching weight loss outcomes comparable to bariatric surgery [ 1 , 2 ]. Despite global utilisation, there remain critical clinical and research gaps in structured nutritional guidance for their use. These gaps present a clinical concern, since GLP-1 RA-induced weight loss mirrors several physiological effects of bariatric interventions, potentially resulting in significant reductions in lean mass, micronutrient depletion, altered eating behaviours, gastrointestinal symptoms, and gallstone formation [ 3 ].